az-3102
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Apr 24, 2023 (NCT05758922)
Timeline
Indications
Mechanism of action
- Ceramide glucosyltransferaseINHIBITOR
UGCG inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
OC[C@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CCCCCOCc1ccc(-c2ccccc2)c(F)c1- Mol. weight
- 433.52 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3354637 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07082725 | Phase 3 | Jun 30, 2025 | Azafaros |
| NCT05758922 | Phase 2 | Apr 24, 2023 | Azafaros |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Azafaros | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1